How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?

Affiliations

¹ Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and Carsten Denkert, German Breast Group, Neu-Isenburg, Germany; and Charité University Hospital, Berlin, Germany.

Editorial

Sibylle Loibl et al. J Clin Oncol. 2017.

. 2017 Apr 1;35(10):1029-1030.

doi: 10.1200/JCO.2016.71.3503. Epub 2017 Jan 30.

¹ Sibylle Loibl, German Breast Group, Neu-Isenburg, Germany; and Carsten Denkert, German Breast Group, Neu-Isenburg, Germany; and Charité University Hospital, Berlin, Germany.

No abstract available

Comment on

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, Walls A, Bousamra A, Ramineni M, Sinn B, Hunt K, Buchholz TA, Valero V, Buzdar AU, Yang W, Brewster AM, Moulder S, Pusztai L, Hatzis C, Hortobagyi GN. Symmans WF, et al. J Clin Oncol. 2017 Apr 1;35(10):1049-1060. doi: 10.1200/JCO.2015.63.1010. Epub 2017 Jan 30. J Clin Oncol. 2017. PMID: 28135148 Free PMC article.